[Event Report] Special International Forum: The Importance of Vaccines and Japan’s Role in Global Health (October 22, 2021)
date : 11/1/2021
Tags: Vaccinations
![[Event Report] Special International Forum: The Importance of Vaccines and Japan’s Role in Global Health (October 22, 2021)](https://hgpi.org/en/wp-content/uploads/sites/2/vaccine-20211022-top-1.jpg)
Health and Global Policy Institute (HGPI) convened an online Special International Forum: “The Importance of Vaccines and Japan’s Role in Global Health.”
The importance of vaccines in the context of global health has started to take up more space in the vaccine policy debate than ever before. As the impact of COVID-19 is felt in developing, as well as developed countries, a global, collaborative framework (ACT-A: Access to COVID-19 Tools Accelerator) to accelerate access to tools related to COVID-19 has been launched. Through the COVAX Facility, a multilateral framework for the procurement and distribution of safe and approved vaccines has been established. Furthermore, international contributions are being made through bilateral vaccine donations. Japan has engaged in various international cooperation initiatives through its Strategy on Global Health Diplomacy, approved by the Cabinet in 2013, and the Basic Design for Peace and Health (Global Health Cooperation), created in 2015.
At the same time, the international supply of COVID-19 vaccines has been unevenly distributed, with middle- and high-income countries receiving more vaccines and low-income countries receiving far fewer. Recently, there have been calls around the world for vaccines to be classified as “Global Public Goods” and it is essential that we expand the conversation to promote public and stakeholder interest and understanding of international contributions and diplomatic issues related to COVID-19.
The Special International Forum focused on Japan’s global provision of COVID-19 vaccines, the COVAX Facility’s current status and prospects, and Japan’s future role in health diplomacy. Experts from industry, government, academia, and the private sector in Japan and abroad engaged in discussions on the significance of medicines, including vaccines, to global health and the role expected of Japan moving forward.
■Date: Friday, October 22, 2021, 15:30-18:00 JST
■Format: Zoom Webinar
■Participation Fee: Free
■Language: English and Japanese (simultaneous interpretation available)
■Host: Health and Global Policy Institute
■Co-host: The British Embassy Japan
■Program: (Titles omitted)
15:30-15:35 Opening Address (1)
Kiyoshi Kurokawa (Chairman, Health and Global Policy Institute)
15:35-15:40 Opening Address (2)
Julia Longbottom (British Ambassador to Japan)
15:40-15:45 Event Overview
Ryoji Noritake (CEO & Board Member, Health and Global Policy Institute)
15:45-16:00 Keynote Speech (1) Lessons Learned from UK’s Vaccine Rollout and Global Health Strategy
Saul Walker (Deputy Head of COVID-19 Vaccines, Therapeutics and Diagnostics Strategy, Foreign Commonwealth and Development Office(FCDO), UK)
16:00-16:15 Keynote Speech (2) Japan’s International Collaboration Efforts in the COVID-19 Era
Satoshi Ezoe (Director, Global Health Policy Division, Ministry of Foreign Affairs, Japan)
Panelists:
Mihoko Kashiwakura (Head of East Asia Relations, Bill & Melinda Gates Foundation)
Keizo Takemi (Member of the House of Councilors; WHO Goodwill Ambassador for UHC)
Atsushi Sunami (President, The Sasakawa Peace Foundation)
Kayo Takuma (Professor, Tokyo Metropolitan University)
Suwit Wibulpolprasert (Senior Advisor, Thai Ministry of Health)
Moderator:
Joji Sugawara (Manager, Health and Global Policy Institute)
17:50-18:00 Closing Remarks
Noriko Furuya (Member of the House of Representatives; Acting Chairperson, Association for the Promotion of Improved Public Health, Parliamentary Group for Vaccines and Prevention)
*Please find out the brochure at the bottom of this website for more information.
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Public Comment Submission] “GX2040 Vision (Draft)” (January 26, 2025)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Public Comment Submission] “Plan for Global Warming Countermeasures (Draft)” (January 26, 2025)
- [Public Comment Submission] “Third Phase of The Healthcare Policy (Draft)” (February 3, 2025)
- [Policy Recommendations] Achieving a Sustainable Society of Health and Longevity Through the Integration of Environment and Healthcare-Incorporating a Planetary Health Perspective into the 3rd Phase of The Healthcare Policy-(December 20, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Publication Report] The Child Health Project Publishes Family Mental Health Booklet “Learning and Practicing at Home – Stress Management for Children with Intellectual Disabilities” (February 3, 2025)
Featured Posts
-
2025-02-12
[Registration Open] (Webinar) The 131st HGPI Seminar “The Policy Process of the Kyoto City Caregiver Ordinance” (March 19, 2025)
-
2025-02-20
[Registration Open] The Cardiovascular Disease (CVD) Control Promotion Project Online Global Symposium “Exploring the Future of CVD Control Through Policy Case Studies in the Asia-Pacific Region” (March 13, 2025)
-
2025-03-03
[Registration Open] (Webinar) HGPI Special Seminar “Insights from Harvard Students on Fukushima’s Recover” (March 21, 2025 EDT | March 22, 2025 JST)
-
2025-03-13
[HGPI Policy Column] (No.54) From the Kidney Disease Control Promotion Project “The Promotion of Kidney Disease Measures Through Multi-Stakeholder Collaboration”
-
2025-03-13
[HGPI Policy Column] (No.55) From the Kidney Disease Control Promotion Project “What Is Required from a Patient Perspective for Continuity of Treatment for Chronic Kidney Disease (CKD): Dietary Therapy Edition”